Sunshine Biopharma (NASDAQ:SBFM) reported its Q1 2025 financial results, showing revenue growth of 18% to $8.9 million compared to $7.5 million in Q1 2024. The company's gross profit increased to $2.7 million, while net loss decreased to $1.18 million from $1.28 million year-over-year. Key operational highlights include the appointment of Michel Roy as Chief Commercial Officer and the launch of 6 new generic prescription drugs. The company also made progress in its research, completing additional studies on its K1.1 mRNA Lipid Nanoparticle product for hepatocellular carcinoma treatment. Despite revenue growth, the company continues to operate at a loss with increased G&A expenses of $4.03 million.
Sunshine Biopharma (NASDAQ:SBFM) ha comunicato i risultati finanziari del primo trimestre 2025, registrando una crescita dei ricavi del 18% a 8,9 milioni di dollari rispetto ai 7,5 milioni del primo trimestre 2024. Il margine lordo è aumentato a 2,7 milioni di dollari, mentre la perdita netta si è ridotta a 1,18 milioni di dollari da 1,28 milioni anno su anno. Tra i principali eventi operativi si segnalano la nomina di Michel Roy come Chief Commercial Officer e il lancio di 6 nuovi farmaci generici con prescrizione. L'azienda ha inoltre fatto progressi nella ricerca, completando ulteriori studi sul prodotto K1.1 mRNA Lipid Nanoparticle per il trattamento del carcinoma epatocellulare. Nonostante la crescita dei ricavi, la società continua a operare in perdita con spese generali e amministrative aumentate a 4,03 milioni di dollari.
Sunshine Biopharma (NASDAQ:SBFM) informó sus resultados financieros del primer trimestre de 2025, mostrando un crecimiento de ingresos del 18% hasta 8,9 millones de dólares en comparación con 7,5 millones en el primer trimestre de 2024. La ganancia bruta aumentó a 2,7 millones de dólares, mientras que la pérdida neta disminuyó a 1,18 millones de dólares desde 1,28 millones interanual. Entre los aspectos operativos clave se incluyen el nombramiento de Michel Roy como Chief Commercial Officer y el lanzamiento de 6 nuevos medicamentos genéricos con receta. La compañía también avanzó en su investigación, completando estudios adicionales sobre su producto K1.1 mRNA Lipid Nanoparticle para el tratamiento del carcinoma hepatocelular. A pesar del crecimiento en ingresos, la empresa sigue operando con pérdidas y con gastos generales y administrativos incrementados a 4,03 millones de dólares.
Sunshine Biopharma (NASDAQ:SBFM)는 2025년 1분기 재무 실적을 발표하며, 2024년 1분기 750만 달러 대비 18% 증가한 890만 달러의 매출을 기록했습니다. 회사의 총이익은 270만 달러로 증가했으며, 순손실은 전년 동기 대비 128만 달러에서 118만 달러로 감소했습니다. 주요 운영 사항으로는 Michel Roy를 최고 상업 책임자(Chief Commercial Officer)로 임명하고, 6종의 새로운 일반 처방약을 출시한 점이 포함됩니다. 또한 간세포암 치료를 위한 K1.1 mRNA 지질 나노입자 제품에 대한 추가 연구를 완료하는 등 연구 개발도 진전을 이루었습니다. 매출이 성장했음에도 불구하고 회사는 계속 손실을 기록하고 있으며, 일반관리비는 403만 달러로 증가했습니다.
Sunshine Biopharma (NASDAQ:SBFM) a publié ses résultats financiers du premier trimestre 2025, affichant une croissance du chiffre d'affaires de 18% à 8,9 millions de dollars contre 7,5 millions au premier trimestre 2024. Le bénéfice brut a augmenté pour atteindre 2,7 millions de dollars, tandis que la perte nette a diminué à 1,18 million de dollars contre 1,28 million sur un an. Parmi les faits marquants opérationnels figurent la nomination de Michel Roy au poste de Chief Commercial Officer et le lancement de 6 nouveaux médicaments génériques sur ordonnance. L'entreprise a également progressé dans ses recherches en complétant des études supplémentaires sur son produit K1.1 mRNA Lipid Nanoparticle destiné au traitement du carcinome hépatocellulaire. Malgré la croissance du chiffre d'affaires, la société continue d'opérer à perte avec une augmentation des frais généraux et administratifs à 4,03 millions de dollars.
Sunshine Biopharma (NASDAQ:SBFM) meldete seine Finanzergebnisse für das erste Quartal 2025 und verzeichnete ein Umsatzwachstum von 18% auf 8,9 Millionen US-Dollar im Vergleich zu 7,5 Millionen US-Dollar im ersten Quartal 2024. Der Bruttogewinn stieg auf 2,7 Millionen US-Dollar, während der Nettoverlust von 1,28 Millionen auf 1,18 Millionen US-Dollar im Jahresvergleich sank. Zu den wichtigsten operativen Highlights zählen die Ernennung von Michel Roy zum Chief Commercial Officer sowie die Einführung von 6 neuen generischen verschreibungspflichtigen Medikamenten. Das Unternehmen machte zudem Fortschritte in der Forschung und schloss weitere Studien zu seinem K1.1 mRNA Lipid-Nanopartikel-Produkt zur Behandlung von hepatozellulärem Karzinom ab. Trotz Umsatzwachstum arbeitet das Unternehmen weiterhin mit Verlust und verzeichnet gestiegene Verwaltungs- und Gemeinkosten von 4,03 Millionen US-Dollar.
Positive
Revenue increased 18% year-over-year to $8.9 million
Net loss decreased by 8% to $1.18 million from $1.28 million
Successfully launched 6 new generic prescription drugs
Gross profit improved to $2.73 million from $2.35 million
Sunshine Biopharma shows improved revenue growth but remains unprofitable with concerning margin trends despite pipeline expansion.
Sunshine Biopharma's Q1 2025 results reveal mixed signals for investors. While the 18% revenue growth to $8.9 million demonstrates strong top-line momentum, the company continues to operate at a loss. The year-over-year revenue increase of approximately $1.36 million is encouraging, suggesting their commercial strategy is gaining traction.
Looking deeper at the financials, there are concerning trends beneath the headline growth. Gross profit increased by only 16% (from $2.35 million to $2.73 million), indicating slight margin compression compared to revenue growth. More troubling is the 8.7% increase in G&A expenses to $4.03 million, which significantly exceeds the company's gross profit. This administrative cost burden remains a substantial obstacle to profitability.
The net loss decreased marginally by $104,030 or approximately 8.1%, which represents incremental progress but still leaves Sunshine with a substantial $1.18 million quarterly deficit. At this burn rate, continued financing activities may be necessary.
On the operational front, the launch of six new generic prescription drugs across antibiotics, gastrointestinal disorders, and schizophrenia treatments demonstrates portfolio diversification efforts. This expanded product lineup likely contributed to revenue growth and represents potential for continued sales expansion in future quarters.
The appointment of Michel Roy as Chief Commercial Officer signals the company's focus on improving commercial performance. Meanwhile, progress with their K1.1 mRNA Lipid Nanoparticle product for hepatocellular carcinoma represents longer-term value potential, though commercialization timelines remain unclear. This preclinical advancement offers a glimpse of pipeline development beyond their current generic portfolio.
FORT LAUDERDALE, FL / ACCESS Newswire / May 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2025 first quarter report on Form 10-Q on Thursday, May 15, 2025. The following are highlights of the report:
Revenues in first quarter of 2025 were $8.9 million, up 18% over revenue of the same period last year.
Appointed a new Chief Commercial Officer, Mr. Michel Roy, a leader in the pharma industry.
Launched 6 new generic prescription drugs including two antibiotics, two drugs for gastrointestinal disorders and two drugs for schizophrenia.
Completed additional studies on orthotopic human tumor models in mice further confirming the Company's K1.1 mRNA Lipid Nanoparticle product as a novel therapeutic agent for human hepatocellular carcinoma.
"We are thrilled to report strong financial results for the first quarter of 2025, with an 18% increase in revenues compared to the same period last year. This growth reflects the continued dedication of our team, the trust of our customers, and the strength of our strategic initiatives. Sunshine Biopharma remains steadfast in its commitment to innovation, operational excellence, and delivering value to our stakeholders. As we move forward, we are focused on expanding our product pipeline, strengthening partnerships, and driving long-term sustainable growth. Our success is a testament to the resilience and ingenuity of our organization, and I am confident that we will continue to build on this momentum throughout the year," said Dr. Steve Slilaty, CEO of the Company.
The following are key elements of the Income Statement contained in the Company's 2025 first quarter report:
2025Q1
2024Q1
Revenue
$
8,901,341
$
7,541,046
Gross Profit
$
2,730,426
$
2,354,337
General & Administrative Expenses
$
4,026,176
$
3,704,926
Net Loss
$
1,179,771
$
1,283,801
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and 13 additional drugs scheduled to be launched in the remainder of 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
All registered trademarks are the property of their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
What was Sunshine Biopharma's (SBFM) revenue in Q1 2025?
Sunshine Biopharma reported revenue of $8.9 million in Q1 2025, an 18% increase from $7.5 million in Q1 2024.
How many new generic drugs did SBFM launch in Q1 2025?
Sunshine Biopharma launched 6 new generic prescription drugs, including two antibiotics, two drugs for gastrointestinal disorders, and two drugs for schizophrenia.
What was Sunshine Biopharma's (SBFM) net loss in Q1 2025?
SBFM reported a net loss of $1.18 million in Q1 2025, compared to a net loss of $1.28 million in Q1 2024.
Who is the new Chief Commercial Officer of Sunshine Biopharma?
Mr. Michel Roy was appointed as the new Chief Commercial Officer of Sunshine Biopharma.
What progress did SBFM make in cancer research during Q1 2025?
SBFM completed additional studies on orthotopic human tumor models in mice, confirming their K1.1 mRNA Lipid Nanoparticle product as a potential therapeutic agent for human hepatocellular carcinoma.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
